Find the Perfect Plan for Your Investment Journey
Last Price
52 Week Range
$55.54 - $113.51
Next Earnings Date
May 08 2025
Next Earnings Date
May 08 2025
Last Price
Market Cap | $5.46B |
EV | $4.34B |
Shares Outstanding | 76.55M |
Beta | 1.42 |
Analyst Rating | BUY |
Analyst Target Price | $111.70 |
P/E 2025E | - |
P/Revenue 2025E | - |
Revenue | - |
EPS | -22.70% |
Operating Cash Flow | -66.60% |
Free Cash Flow | 23.70% |
Revenue | - |
EPS | 14.00% |
Operating Cash Flow | -32.60% |
Free Cash Flow | -7.80% |
Gross Margin 2025E | - |
Net Profit Margin 2025E | - |
ROE 2025E | -31.65% |
ROCE 2024 | -29.46% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Nuvalent, Inc.
NUVL
Sector
Healthcare
Industry
Biotechnology
CEO
Porter, James
Employees
142
Website
www.nuvalent.comIPO Date
2021-07-29
Headquarters
One Broadway, 14th Floor, Cambridge, Massachusetts, 02142, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved